



Uscom Limited
ABN 35 091 028 090
Suite 1, Level 7, 10 Loftus Street
Sydney NSW 2000 Australia
T +612 9247 4144 F +612 9247 8157
www.uscom.com.au

MARKET ANNOUNCEMENT

Uscom AGM Scheduled to 30th November

SYDNEY, Australia, Thursday 13th October 2016: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**), a revenue stage, cardiovascular medical devices company, today notified the market that the Annual General Meeting (AGM) of the Company is to be rescheduled from the 9th of November 2016 to the 30th November 2016. The AGM will be held at 10:30am at the Uscom Sydney office – Level 7, 10-12 Loftus St, Sydney, 2000.

The meeting was rescheduled to accommodate sales and distribution meetings with international executives at the Medica convention in Dusseldorf, Germany. Medica is the world's largest medical products trade fair with an anticipated 135,000 visitors and 4,500 medical device manufacturers exhibiting. Uscom is an exhibitor and has satellite meetings booked to potential new global distributors. With the impending release of the Uscom BP+ central blood pressure and vascular health monitor, and the accompanying BP+Reporter archiving and analysis software, and the Uscom SpiroSonic series of high fidelity digital ultrasonic spirometers and accompanying SpiroReporter software, these meetings are vital to establish early paths to market.

Executive Chairman of Uscom, Associate Professor Rob Phillips said *"Nothing is more important in terms of achieving revenue targets for the next few years than sales. As our two new product series are brought to manufacture and global markets this is our best opportunity to meet and appoint high quality distributors. Uscom executives are scheduled for distributor meetings at Medica and at satellite meetings in Europe over the time of the scheduled AGM, and rather than abandon these commercially vital meetings we have rescheduled the AGM. The meetings are with senior executives from global distribution companies with scale and reach, and we anticipate successful outcomes from a number of these meetings. Our BP+ and SpiroSonic devices are being prepared for sale in the major global medical device jurisdictions of China, Europe and the USA. Our sample runs are almost complete and regulatory submissions are in preparation for all jurisdictions. Appointment of high-level distributors in advance of these approvals will ensure an early and seamless transition to revenue."*

Uscom is the manufacturer of the USCOM 1A, the Uscom BP+, and Uscom SpiroSonic digital ultrasonic spirometry technologies and distributes and sells these devices worldwide. These premium digital devices are changing the way clinician diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis, guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, for advanced monitoring of hypertensiona and pre-eclampsia, and in clinical and home care asthma and COPD monitoring.



Uscom Limited
ABN 35 091 028 090
Suite 1, Level 7, 10 Loftus Street
Sydney NSW 2000 Australia
T +612 9247 4144 F +612 9247 8157
www.uscom.com.au

About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium cardiovascular and pulmonary medical devices. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A, Uscom BP+ and the Uscom SpiroSonic spirometers. All Uscom devices are premium resolution, and deploy innovative and practice leading technologies, with FDA, CE, CFDA and TGA regulatory approval granted or in application, and which are currently being marketed into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotrope and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra systolic oscillometric Central Blood Pressure monitor which measures blood pressure and blood pressure waveforms only previously available using cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.

Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and disinfect, don't require calibration, and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices are specialised for assessment of asthma, COPD, sleep disordered breathing, occupational diseases and monitoring of pulmonary therapeutic compliance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Executive Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary
secretary@uscom.com.au